Revvity Announces Financial Results for the Third Quarter of 2026
REVVITY, INC. (RVTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE November 3, 2026 Revvity Announces Financial Results for the Third Quarter of 2026 • Revenue of $729 million; pro forma revenue of $710 million; 7% pro forma revenue growth; 7% pro forma organic revenue growth • GAAP EPS from continuing operations of $0.56 ;
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive short‑term buying interest, while the upcoming Investor Day could add further catalyst value.
Market read
First‑report earnings with raised guidance for a mid‑cap biotech firm; high relevance for traders focused on life‑science equities.
What to watch
The pending divestiture of the China Immunodiagnostics business may introduce execution risk later in 2027.
Revvity Announces Financial Results for the Third Quarter of 2026
Third-quarter pro forma revenue growth was 7%, pro forma organic revenue growth was 7%, and pro forma adjusted operating profit margin was 29.4%, compared with 26.0% in the same period a year ago. The company raised full-year guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 revenueGAAP | $729M | – | – |
| Q3 2026 pro forma revenueother | $710M | – | 7% |
| Q3 2026 pro forma organic revenue growthnon-GAAP | 7% | – | – |
| Q3 2026 cost of revenueGAAP | 310,320 | – | – |
| Q3 2026 selling, general and administrative expensesGAAP | 275,330 | – | – |
| Q3 2026 research and development expensesGAAP | 48,108 | – | – |
| Q3 2026 operating income from continuing operationsGAAP | $95M | – | – |
| Q3 2026 operating profit margin from continuing operationsGAAP | 13.1% | – | – |
| Q3 2026 pro forma operating incomeother | $102M | – | – |
| Q3 2026 pro forma operating profit marginother | 14.3% | – | – |
| Q3 2026 adjusted operating incomenon-GAAP | $209M | – | – |
| Q3 2026 adjusted operating profit marginnon-GAAP | 28.7% | – | – |
| Q3 2026 pro forma adjusted operating incomenon-GAAP | $209M | – | – |
| Q3 2026 pro forma adjusted operating profit marginnon-GAAP | 29.4% | – | – |
| Q3 2026 income from continuing operationsGAAP | 62,621 | – | – |
| Q3 2026 net incomeGAAP | $62.30M | – | – |
| Q3 2026 GAAP EPS from continuing operationsGAAP | $0.56 | – | – |
| Q3 2026 GAAP pro forma EPS from continuing operationsGAAP | $0.60 | – | – |
| Q3 2026 adjusted EPS from continuing operationsnon-GAAP | $1.38 | – | – |
| Q3 2026 pro forma adjusted EPS from continuing operationsnon-GAAP | $1.37 | – | – |
| Q3 2026 net cash provided by operating activitiesGAAP | 166,704 | – | – |
| Q3 2026 net cash provided by operating activities of continuing operationsGAAP | 166,704 | – | – |
| Q3 2026 capital expendituresGAAP | (14,346) | – | – |
| Nine months 2026 revenueGAAP | 2,169,705 | – | – |
| Nine months 2026 pro forma revenueother | 2,107,627 | – | 7% |
| Nine months 2026 pro forma organic revenue growthnon-GAAP | 5% | – | – |
| Nine months 2026 operating income from continuing operationsGAAP | 260,343 | – | – |
| Nine months 2026 operating profit margin from continuing operationsGAAP | 12.0% | – | – |
| Nine months 2026 adjusted operating incomenon-GAAP | 588,184 | – | – |
| Nine months 2026 adjusted operating profit marginnon-GAAP | 27.1% | – | – |
| Nine months 2026 net incomeGAAP | 154,837 | – | – |
| Nine months 2026 GAAP EPS from continuing operationsGAAP | $1.40 | – | – |
| Nine months 2026 adjusted EPS from continuing operationsnon-GAAP | $3.85 | – | – |
| Nine months 2026 net cash provided by operating activitiesGAAP | 473,877 | – | – |
| Nine months 2026 net cash provided by operating activities of continuing operationsGAAP | 484,534 | – | – |
| Nine months 2026 capital expendituresGAAP | (45,194) | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Life SciencesThird quarter 2026 adjusted operating income was $119 million, as compared to $101 million in the same period a year ago. Adjusted operating profit margin was 31.5% as a percentage of revenue, as compared to 29.5% in the same period a year ago. | $380M | – | Pro forma revenue increased 11% and pro forma organic revenue increased 9% |
| DiagnosticsThird quarter 2026 adjusted operating income was $104 million, as compared to $89 million in the same period a year ago. Adjusted operating profit margin was 29.9% as a percentage of revenue, as compared to 25.1% in the same period a year ago. | $349M | – | Pro forma revenue increased 4% and pro forma organic revenue increased 5% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full Year 2026 outlook
- Revenueapproximately $2.86 billion
- Notepro forma organic revenue growth of approximately 5%
- Notepro forma adjusted earnings per share of $5.40-$5.45
- NoteGuidance is provided on a pro forma basis only and excludes China IDX.
Capital returns
- Purchases of common stock: $ (95) for the three months ended October 4, 2026, compared with $ (205,029) for the three months ended September 28, 2025.
- Purchases of common stock: $ (102,583) for the nine months ended October 4, 2026, compared with $ (652,530) for the nine months ended September 28, 2025.
- Dividends paid: $ (7,811) for the three months ended October 4, 2026, compared with $ (8,130) for the three months ended September 28, 2025.
- Dividends paid: $ (23,465) for the nine months ended October 4, 2026, compared with $ (24,845) for the nine months ended September 28, 2025.
What drove it
- Total pro forma revenue growth from continuing operations was 7%, with a -1% effect of foreign exchange rates and a 1% effect of acquisitions including purchase accounting adjustments and impact of divested businesses.
- Life Sciences pro forma revenue growth was 11% and pro forma organic revenue growth was 9%.
- Diagnostics pro forma revenue growth was 4% and pro forma organic revenue growth was 5%.
- Adjusted operating profit margin was 28.7%, compared with 26.1% in the same period a year ago.
- Pro forma adjusted operating profit margin was 29.4%, compared with 26.0% in the same period a year ago.
Concerns
- Diagnostics reported revenue of $349 million, compared with $356 million in the same period a year ago.
- China IDX represented approximately 6% of the Company’s total revenue in fiscal year 2025 and is expected to be divested by the end of 2027, subject to customary closing conditions and regulatory approvals.
- Restructuring and other was 28,357 in the third quarter of 2026, compared with 9,926 in the same period a year ago.
- Cash and cash equivalents were $ 592,799 as of October 4, 2026, compared with $ 919,860 as of December 28, 2025.
What to watch
- Full-year 2026 pro forma revenue guidance of approximately $2.86 billion.
- Full-year 2026 pro forma organic revenue growth guidance of approximately 5%.
- Full-year 2026 pro forma adjusted earnings per share guidance of $5.40-$5.45.
- The expected closing of the China IDX divestiture by the end of 2027.
- Revvity's 2026 Investor Day on November 13, 2026.
Balance sheet and cash flow
- Cash and cash equivalents: $ 592,799 as of October 4, 2026, compared with $ 919,860 as of December 28, 2025.
- Long-term debt: $ 2,634,062 as of October 4, 2026, compared with $ 2,631,236 as of December 28, 2025.
- Current portion of long-term debt: $ — as of October 4, 2026, compared with $ 588,828 as of December 28, 2025.
- Payments of senior unsecured notes: $ (571,193) for the three months and nine months ended October 4, 2026.
- Net cash used in financing activities: $ (575,614) for the three months ended October 4, 2026, compared with $ (215,074) for the three months ended September 28, 2025.
- Net cash used in financing activities: $ (687,669) for the nine months ended October 4, 2026, compared with $ (681,213) for the nine months ended September 28, 2025.
- Net decrease in cash, cash equivalents, and restricted cash: $ (430,215) for the three months ended October 4, 2026, compared with $ (60,415) for the three months ended September 28, 2025.
Analysis
Revvity reported third-quarter revenue of $729 million, compared with $699 million in the same period a year ago. On the pro forma basis used for forward guidance and excluding China IDX, revenue was $710 million versus $660 million, with 7% pro forma revenue growth and 7% pro forma organic revenue growth. The company said it has entered into a definitive agreement to divest China IDX, which represented approximately 6% of total revenue in fiscal year 2025.
Growth was led by Life Sciences. That segment recorded revenue of $380 million, compared with $343 million a year ago, with pro forma revenue growth of 11% and pro forma organic revenue growth of 9%. Diagnostics revenue was $349 million, compared with $356 million a year ago, while pro forma revenue growth was 4% and pro forma organic revenue growth was 5%. The pro forma presentation is particularly important because it excludes China IDX and is the basis for the company’s full-year outlook.
Profitability improved on both reported and adjusted measures. GAAP operating income from continuing operations was $95 million compared with $82 million, and GAAP operating profit margin was 13.1% compared with 11.7%. Adjusted operating income was $209 million compared with $182 million, lifting adjusted operating profit margin to 28.7% from 26.1%. On a pro forma adjusted basis, operating income was $209 million compared with $172 million and margin was 29.4% compared with 26.0%. GAAP EPS from continuing operations increased to $0.56 from $0.41, while adjusted EPS from continuing operations increased to $1.38 from $1.18.
Cash flow from operations was 166,704 in the third quarter, compared with 138,500, and capital expenditures were (14,346), compared with (18,501). Financing cash outflows included payments of senior unsecured notes of $ (571,193), purchases of common stock of $ (95), and dividends paid of $ (7,811). Cash and cash equivalents were $ 592,799 at October 4, 2026, compared with $ 919,860 at December 28, 2025, while long-term debt was $ 2,634,062 compared with $ 2,631,236.
The company raised full-year 2026 guidance and now forecasts, on a pro forma basis, total revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted earnings per share of $5.40-$5.45. Management’s outlook excludes China IDX. Key items to monitor are the trajectory of Diagnostics growth, the durability of Life Sciences momentum, adjusted-margin performance, and progress toward the expected China IDX divestiture closing by the end of 2027.
Management, verbatim
Our exceptional third quarter performance demonstrates the momentum building across Revvity, as broad-based growth and strong execution drove results meaningfully ahead of our expectations. With end market conditions continuing to improve, a strong pipeline of innovation, and the benefits of our transformation increasingly evident in our results, Revvity is extremely well positioned to capitalize on the opportunities ahead.
Prahlad Singh, president and chief executive officer of Revvity
Not in the filing
stated, not guessed- Prior-quarter comparisons for reported financial metrics were not provided.
- Reported gross margin and adjusted gross margin were not provided.
- Free cash flow value was not provided, although the company defined the measure.
- Full-year 2026 guidance for gross margin, operating expenses, and tax rate was not provided.
- Previous-release outlook was not provided, so no comparison of actual results with prior guidance is available.
- GAAP and non-GAAP tax rates were not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Revvity (NYSE: RVTY) released its Q3 2026 earnings via an SEC Form 8‑K, highlighting revenue growth and an updated full‑year EPS outlook.
Ticker impact
Revvity reported Q3 2026 results with $729M revenue and raised full-year guidance to $5.40-$5.45 EPS.
likely upward pressure as the market prices in the raised guidance
Revenue and EPS both exceeded prior-year levels and management issued raised guidance, which typically supports a price rally.
Market effects
Life sciences and diagnostics peers may see modest upside as Revvity's strong quarter signals sector demand.
U.S. biotech and medical device stocks could benefit from the positive earnings backdrop.
Limited to investors tracking U.S. listed life‑science companies.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pull‑back.
Key entities
- companyRevvity, Inc.
Medical device and life‑science solutions provider.
- executivePrahlad Singh
President and CEO of Revvity who commented on the results.
